Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter of 2025, with year-over-year revenue ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

Tempus AI delivered a record quarter, supported by strong revenue growth across its segments and a landmark $200 million agreement with AstraZeneca and Pathos. The company raised its full-year ...

CHICAGO, May 05, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of ...

Tempus AI Inc. (TEM) reported its first-quarter 2025 earnings, showcasing a robust revenue increase of 75.4% year-over-year, reaching $255.7 million, surpassing the forecast of $248.5 million.